

Mohammad T Elnakish

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8491504/publications.pdf>

Version: 2024-02-01

28
papers

563
citations

623734

14
h-index

642732

23
g-index

28
all docs

28
docs citations

28
times ranked

968
citing authors

#	ARTICLE	IF	CITATIONS
1	Effect of hypothyroidism on contractile performance of isolated end-stage failing human myocardium. <i>PLoS ONE</i> , 2022, 17, e0265731.	2.5	2
2	Impact of etiology on force and kinetics of left ventricular end-stage failing human myocardium. <i>Journal of Molecular and Cellular Cardiology</i> , 2021, 156, 7-19.	1.9	14
3	Modeling heart failure in animal models for novel drug discovery and development. <i>Expert Opinion on Drug Discovery</i> , 2019, 14, 355-363.	5.0	5
4	Protein Kinase A as a Promising Target for Heart Failure Drug Development. <i>Archives of Medical Research</i> , 2018, 49, 530-537.	3.3	32
5	Assessment of PKA and PKC inhibitors on force and kinetics of non-failing and failing human myocardium. <i>Life Sciences</i> , 2018, 215, 119-127.	4.3	9
6	Mineralocorticoid Receptor Antagonists in Muscular Dystrophy Mice During Aging and Exercise. <i>Journal of Neuromuscular Diseases</i> , 2018, 5, 295-306.	2.6	15
7	Etiology-dependent impairment of relaxation kinetics in right ventricular end-stage failing human myocardium. <i>Journal of Molecular and Cellular Cardiology</i> , 2018, 121, 81-93.	1.9	28
8	Synchronization of Intracellular Ca ²⁺ Release in Multicellular Cardiac Preparations. <i>Frontiers in Physiology</i> , 2018, 9, 968.	2.8	3
9	Antiarrhythmic Activity of NMDA Receptor Antagonists in Humans Versus Animal Models. <i>FASEB Journal</i> , 2018, 32, 901.16.	0.5	0
10	Effects of zacopride, a moderate IK1 channel agonist, on triggered arrhythmia and contractility in human ventricular myocardium. <i>Pharmacological Research</i> , 2017, 115, 309-318.	7.1	16
11	Memantine, an NMDA Receptor Antagonist, Prevents Thyroxine-induced Hypertension, but Not Cardiac Remodeling. <i>Journal of Cardiovascular Pharmacology</i> , 2017, 70, 305-313.	1.9	8
12	Recovery following Thyroxine Treatment Withdrawal, but Not Propylthiouracil, Averts In Vivo and Ex Vivo Thyroxine-Provoked Cardiac Complications in Adult FVB/N Mice. <i>BioMed Research International</i> , 2017, 2017, 1-11.	1.9	8
13	The Effect of Sorafenib, Tadalafil and Macitentan Treatments on Thyroxine-Induced Hemodynamic Changes and Cardiac Abnormalities. <i>PLoS ONE</i> , 2016, 11, e0153694.	2.5	5
14	Role of Oxidative Stress in Thyroid Hormone-Induced Cardiomyocyte Hypertrophy and Associated Cardiac Dysfunction: An Undisclosed Story. <i>Oxidative Medicine and Cellular Longevity</i> , 2015, 2015, 1-16.	4.0	44
15	The Frank-Starling mechanism involves deceleration of cross-bridge kinetics and is preserved in failing human right ventricular myocardium. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2015, 309, H2077-H2086.	3.2	32
16	Differential involvement of various sources of reactive oxygen species in thyroxine-induced hemodynamic changes and contractile dysfunction of the heart and diaphragm muscles. <i>Free Radical Biology and Medicine</i> , 2015, 83, 252-261.	2.9	21
17	Emerging role of oxidative stress in metabolic syndrome and cardiovascular diseases: important role of Rac/NADPH oxidase. <i>Journal of Pathology</i> , 2013, 231, 290-300.	4.5	109
18	Stem cell transplantation as a therapy for cardiac fibrosis. <i>Journal of Pathology</i> , 2013, 229, 347-354.	4.5	49

#	ARTICLE	IF	CITATIONS
19	Cardiomyocyte-specific overexpression of an active form of Rac predisposes the heart to increased myocardial stunning and ischemia-reperfusion injury. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2013, 304, H294-H302.	3.2	21
20	Myocardial Rac1 Exhibits Partial Involvement in Thyroxin-induced Cardiomyocyte Hypertrophy and Its Inhibition Is Not Sufficient to Improve Cardiac Dysfunction or Contractile Abnormalities in Mouse Papillary Muscles. <i>Journal of Cardiovascular Pharmacology</i> , 2013, 61, 536-544.	1.9	13
21	Mesenchymal Stem Cells for Cardiac Regeneration: Translation to Bedside Reality. <i>Stem Cells International</i> , 2012, 2012, 1-14.	2.5	41
22	Vascular Remodeling-associated Hypertension Leads to Left Ventricular Hypertrophy and Contractile Dysfunction in Profilin-1 Transgenic Mice. <i>Journal of Cardiovascular Pharmacology</i> , 2012, 60, 544-552.	1.9	20
23	Rac-Induced Left Ventricular Dilation in Thyroxin-Treated ZmRacD Transgenic Mice: Role of Cardiomyocyte Apoptosis and Myocardial Fibrosis. <i>PLoS ONE</i> , 2012, 7, e42500.	2.5	16
24	Physiologic Cardiac Hypertrophy and Cardiac Dilation: A Comparative Study Using ZmRacD Transgenic Mouse Model. <i>FASEB Journal</i> , 2012, 26, 615.1.	0.5	0
25	The Effect of Selective Antihypertensive Drugs on the Vascular Remodeling-associated Hypertension: Insights From a Profilin1 Transgenic Mouse Model. <i>Journal of Cardiovascular Pharmacology</i> , 2011, 57, 550-558.	1.9	12
26	Cardiac remodeling caused by transgenic overexpression of a corn Rac gene. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2011, 301, H868-H880.	3.2	14
27	Smooth muscle cell expression of a constitutive active form of human Profilin1 accelerates cutaneous wound repair. <i>FASEB Journal</i> , 2011, 25, 930.1.	0.5	0
28	Vascular hypertrophy-associated hypertension of profilin1 transgenic mouse model leads to functional remodeling of peripheral arteries. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2010, 298, H2112-H2120.	3.2	26